Header Logo

Connection

ELIZABETH SHPALL to Fetal Blood

Back to Details
This is a "connection" page, showing publications ELIZABETH SHPALL has written about Fetal Blood.
ELIZABETH SHPALL
Connection Strength
11.827
Fetal Blood
  1. Cord blood expansion has arrived. Blood. 2021 10 21; 138(16):1381-1382.
    View in: PubMed
    Score: 0.625
  2. Metabolic Reprogramming of GMP Grade Cord Tissue Derived Mesenchymal Stem Cells Enhances Their Suppressive Potential in GVHD. Front Immunol. 2021; 12:631353.
    View in: PubMed
    Score: 0.605
  3. Cord Blood Expansion: A Clinical Advance. J Clin Oncol. 2019 02 10; 37(5):363-366.
    View in: PubMed
    Score: 0.513
  4. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol. 2017 05; 177(3):457-466.
    View in: PubMed
    Score: 0.454
  5. Comparison of two methodologies for the enrichment of mononuclear cells from thawed cord blood products: The automated Sepax system versus the manual Ficoll method. Cytotherapy. 2017 Mar; 19(3):433-439.
    View in: PubMed
    Score: 0.447
  6. Expression of a surface antigen (MA6) by peripheral blood CD34+ cells is correlated with improved platelet engraftment and may explain delayed platelet engraftment following cord blood transplantation. Stem Cells Dev. 2015 May 01; 24(9):1066-72.
    View in: PubMed
    Score: 0.395
  7. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.395
  8. Low rate of infusional toxicity after expanded cord blood transplantation. Cytotherapy. 2014 Aug; 16(8):1153-7.
    View in: PubMed
    Score: 0.368
  9. The development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation. Clin Lymphoma Myeloma Leuk. 2014 Feb; 14(1):e1-5.
    View in: PubMed
    Score: 0.359
  10. Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease. Cytotherapy. 2014 Jan; 16(1):90-100.
    View in: PubMed
    Score: 0.359
  11. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013; 8(10):e76781.
    View in: PubMed
    Score: 0.359
  12. Cord blood graft engineering. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S74-8.
    View in: PubMed
    Score: 0.335
  13. Umbilical cord blood transplantation: a maturing technology. Hematology Am Soc Hematol Educ Program. 2012; 2012:215-22.
    View in: PubMed
    Score: 0.317
  14. Mesenchymal stem cells in ex vivo cord blood expansion. Best Pract Res Clin Haematol. 2011 Mar; 24(1):83-92.
    View in: PubMed
    Score: 0.298
  15. Novel cord blood transplant therapies. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S39-45.
    View in: PubMed
    Score: 0.291
  16. Ex vivo expansion of umbilical cord blood for transplantation. Best Pract Res Clin Haematol. 2010 Jun; 23(2):245-57.
    View in: PubMed
    Score: 0.284
  17. Overcoming the barriers to umbilical cord blood transplantation. Cytotherapy. 2010 Apr; 12(2):121-30.
    View in: PubMed
    Score: 0.280
  18. CD3(+) and/or CD14(+) depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34(+) cell yields. Bone Marrow Transplant. 2010 Jun; 45(6):1000-7.
    View in: PubMed
    Score: 0.272
  19. Ex vivo expansion of cord blood. Bone Marrow Transplant. 2009 Nov; 44(10):673-81.
    View in: PubMed
    Score: 0.271
  20. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplant. 2008 May; 41(9):771-8.
    View in: PubMed
    Score: 0.241
  21. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy. 2006; 8(2):149-57.
    View in: PubMed
    Score: 0.209
  22. Ex vivo expansion of umbilical cord blood. Cytotherapy. 2005; 7(3):243-50.
    View in: PubMed
    Score: 0.195
  23. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. Cytotherapy. 2004; 6(4):311-7.
    View in: PubMed
    Score: 0.182
  24. Engineered cord blood megakaryocytes evade killing by allogeneic T-cells for refractory thrombocytopenia. Front Immunol. 2022; 13:1018047.
    View in: PubMed
    Score: 0.166
  25. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant. 2002; 8(7):368-76.
    View in: PubMed
    Score: 0.158
  26. Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells. Blood. 2021 02 04; 137(5):624-636.
    View in: PubMed
    Score: 0.149
  27. CD34+ cell content of 126?341 cord blood units in the US inventory: implications for transplantation and banking. Blood Adv. 2019 04 23; 3(8):1267-1271.
    View in: PubMed
    Score: 0.131
  28. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study. Stem Cells Transl Med. 2018 07; 7(7):521-529.
    View in: PubMed
    Score: 0.123
  29. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018 02; 32(2):520-531.
    View in: PubMed
    Score: 0.116
  30. Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
    View in: PubMed
    Score: 0.111
  31. Non-fucosylated CB CD34+ cells represent a good target for enforced fucosylation to improve engraftment following cord blood transplantation. Cytotherapy. 2017 02; 19(2):285-292.
    View in: PubMed
    Score: 0.111
  32. PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia. Cytotherapy. 2016 08; 18(8):995-1001.
    View in: PubMed
    Score: 0.109
  33. IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood. 2016 09 08; 128(10):1346-61.
    View in: PubMed
    Score: 0.109
  34. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells. Cytotherapy. 2016 08; 18(8):985-994.
    View in: PubMed
    Score: 0.108
  35. Advances in umbilical cord blood manipulation-from niche to bedside. Nat Rev Clin Oncol. 2015 Mar; 12(3):163-74.
    View in: PubMed
    Score: 0.097
  36. Ex vivo fucosylation of third-party human regulatory T cells enhances anti-graft-versus-host disease potency in vivo. Blood. 2015 Feb 26; 125(9):1502-6.
    View in: PubMed
    Score: 0.097
  37. Is there an expiration date for a cord blood unit in storage? Bone Marrow Transplant. 2014 Aug; 49(8):1109-12.
    View in: PubMed
    Score: 0.093
  38. FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. Bone Marrow Transplant. 2014 Jun; 49(6):793-9.
    View in: PubMed
    Score: 0.093
  39. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy. 2014 Jan; 16(1):84-9.
    View in: PubMed
    Score: 0.089
  40. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013 Feb 01; (72):e50070.
    View in: PubMed
    Score: 0.085
  41. Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012; 7(12):e51390.
    View in: PubMed
    Score: 0.085
  42. Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus. J Vis Exp. 2012 May 07; (63):e3627.
    View in: PubMed
    Score: 0.081
  43. Ex?vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2R?(null) mice. Exp Hematol. 2012 Jun; 40(6):445-56.
    View in: PubMed
    Score: 0.080
  44. Activation of Wnt signaling arrests effector differentiation in human peripheral and cord blood-derived T lymphocytes. J Immunol. 2011 Nov 15; 187(10):5221-32.
    View in: PubMed
    Score: 0.078
  45. Identification and frequency of CCR5?32/?32 HIV-resistant cord blood units from Houston area hospitals. HIV Med. 2011 Sep; 12(8):481-6.
    View in: PubMed
    Score: 0.075
  46. Umbilical cord blood transplantation. Clin Adv Hematol Oncol. 2010 Nov; 8(11):786-801.
    View in: PubMed
    Score: 0.073
  47. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation. Blood. 2010 Apr 01; 115(13):2695-703.
    View in: PubMed
    Score: 0.069
  48. Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells. Stem Cells. 2009 Aug; 27(8):1932-40.
    View in: PubMed
    Score: 0.067
  49. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes. Blood. 2009 Aug 27; 114(9):1958-67.
    View in: PubMed
    Score: 0.066
  50. De novo T-lymphocyte responses against baculovirus-derived recombinant influenzavirus hemagglutinin generated by a naive umbilical cord blood model of dendritic cell vaccination. Vaccine. 2009 Mar 04; 27(10):1479-84.
    View in: PubMed
    Score: 0.065
  51. Cord blood stem cell therapy for acquired immune deficiency syndrome. Stem Cells Dev. 2009 Jan-Feb; 18(1):1-2.
    View in: PubMed
    Score: 0.064
  52. Mycobacterium tuberculosis infection: a rare late complication after cord blood hematopoietic SCT. Bone Marrow Transplant. 2009 Apr; 43(8):667-8.
    View in: PubMed
    Score: 0.064
  53. PET imaging of T cells derived from umbilical cord blood. Leukemia. 2009 Mar; 23(3):620-2.
    View in: PubMed
    Score: 0.063
  54. Risk of transmission of herpesviruses through cord blood transplantation. Biol Blood Marrow Transplant. 2005 Jan; 11(1):35-8.
    View in: PubMed
    Score: 0.049
  55. Umbilical cord blood-derived cells for tissue repair. Cytotherapy. 2005; 7(3):258-61.
    View in: PubMed
    Score: 0.049
  56. A Randomized, Placebo-Controlled, Phase II Trial of Intravenous Allogeneic Non-HLA Matched, Unrelated Donor, Cord Blood Infusion for Ischemic Stroke. Stem Cells Transl Med. 2024 Feb 14; 13(2):125-136.
    View in: PubMed
    Score: 0.046
  57. Pre-clinical development of cord blood-derived progenitor cell graft expanded ex vivo with cytokines and the polyamine copper chelator tetraethylenepentamine. Cytotherapy. 2004; 6(4):344-55.
    View in: PubMed
    Score: 0.045
  58. Ex Vivo Expanded Cord Blood Natural Killer Cells Combined with Rituximab and High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2024 Feb; 30(2):203.e1-203.e9.
    View in: PubMed
    Score: 0.045
  59. Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future. Stem Cells Transl Med. 2023 03 03; 12(2):55-71.
    View in: PubMed
    Score: 0.043
  60. Ex vivo expanded cord blood cells provide rapid engraftment in fetal sheep but lack long-term engrafting potential. Exp Hematol. 2002 Jun; 30(6):612-6.
    View in: PubMed
    Score: 0.041
  61. Differential long-term and multilineage engraftment potential from subfractions of human CD34+ cord blood cells transplanted into NOD/SCID mice. Proc Natl Acad Sci U S A. 2002 Jan 08; 99(1):413-8.
    View in: PubMed
    Score: 0.040
  62. Optimal umbilical cord blood collection, processing and cryopreservation methods for sustained public cord blood banking. Cytotherapy. 2021 11; 23(11):1029-1035.
    View in: PubMed
    Score: 0.038
  63. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Clin Cancer Res. 2021 07 01; 27(13):3744-3756.
    View in: PubMed
    Score: 0.038
  64. GMP-Compliant Universal Antigen Presenting Cells (uAPC) Promote the Metabolic Fitness and Antitumor Activity of Armored Cord Blood CAR-NK Cells. Front Immunol. 2021; 12:626098.
    View in: PubMed
    Score: 0.037
  65. Graft-versus-leukemia-induced complete remission following unrelated umbilical cord blood transplantation for acute leukemia. Bone Marrow Transplant. 2000 Dec; 26(11):1251-4.
    View in: PubMed
    Score: 0.037
  66. Increased expansion and differentiation of cord blood products using a two-step expansion culture. Exp Hematol. 2000 Oct; 28(10):1181-6.
    View in: PubMed
    Score: 0.036
  67. Guidelines for Cord Blood Unit Selection. Biol Blood Marrow Transplant. 2020 12; 26(12):2190-2196.
    View in: PubMed
    Score: 0.036
  68. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplant. 2000 Jul; 26(1):109-11.
    View in: PubMed
    Score: 0.036
  69. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 02 06; 382(6):545-553.
    View in: PubMed
    Score: 0.035
  70. Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients. Biol Blood Marrow Transplant. 2020 04; 26(4):745-757.
    View in: PubMed
    Score: 0.034
  71. Diphtheria toxin A gene-mediated HIV-1 protection of cord blood-derived T cells in the SCID-hu mouse model. J Hematother. 1998 Aug; 7(4):319-31.
    View in: PubMed
    Score: 0.031
  72. Comparison of retroviral-mediated gene transfer into cultured human CD34+ hematopoietic progenitor cells derived from peripheral blood, bone marrow, and fetal umbilical cord blood. Biol Blood Marrow Transplant. 1997 Nov; 3(5):273-81.
    View in: PubMed
    Score: 0.030
  73. Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood. 1997 Jul 01; 90(1):85-96.
    View in: PubMed
    Score: 0.029
  74. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. Haematologica. 2015 Oct; 100(10):1361-70.
    View in: PubMed
    Score: 0.025
  75. Phenotypic and functional comparison of mobilized peripheral blood versus umbilical cord blood megakaryocyte populations. Cytotherapy. 2015 Apr; 17(4):418-27.
    View in: PubMed
    Score: 0.024
  76. Transmissible cytotoxicity of multiple myeloma cells by cord blood-derived NK cells is mediated by vesicle trafficking. Cell Death Differ. 2015 Jan; 22(1):96-107.
    View in: PubMed
    Score: 0.024
  77. Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood. Cytotherapy. 2010 Oct; 12(6):713-20.
    View in: PubMed
    Score: 0.018
  78. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother. 2010 Sep; 33(7):684-96.
    View in: PubMed
    Score: 0.018
  79. Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1. Fetal Diagn Ther. 1998 Jan-Feb; 13(1):8-14.
    View in: PubMed
    Score: 0.007
  80. Multilineage engraftment in NOD/LtSz-scid/scid mice from mobilized human CD34+ peripheral blood progenitor cells. Biol Blood Marrow Transplant. 1997 Nov; 3(5):236-46.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.